Impact of HPV status on treatment of squamous cell cancer of the oropharynx: What we know and what we need to know

Cancer Letters

Volumn 304, Issue 2, 2011, Pages 71-79

  Tribius, Silke ^a   Ihloff, Anna S ^a   Rieckmann, Thorsten ^a   Petersen, Cordula ^a   Hoffmann, Markus ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Chemoradiotherapy; Clinical trials; HPV; Human papillomavirus; Locally advanced; Oropharyngeal cancer

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; NIMORAZOLE; PACLITAXEL; PLACEBO; TIRAPAZAMINE; VIRUS DNA;

CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; DNA VIRUS INFECTION; DRUG TOLERABILITY; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; LARYNX CANCER; MAJOR CLINICAL STUDY; MEDLINE; MOUTH CANCER; MOUTH CARCINOMA; MULTIPLE CYCLE TREATMENT; OROPHARYNX CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARYNX CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE DISTRIBUTION; RISK ASSESSMENT; SHORT SURVEY; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; VIRUS CARCINOGENESIS; VIRUS LOAD; WART VIRUS;

HUMAN PAPILLOMAVIRUS;

EID: 79952738119     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.02.002     Document Type: Review

References (62)

1. Hunter K.D., Parkinson E.K., Harrison P.R. Profiling early head and neck cancer. Nat. Rev. Cancer 2005, 5:127-135.
2. Globocan, Cancer incidence and mortality worldwide, 2008, <> (accessed 1.11.10). http://www.globocan.iarc.fr/.
3. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. J. Cancer 2010, 46:765-781.
4. Braakhuis B.J., Visser O., Leemans C.R. Oral and oropharyngeal cancer in the Netherlands between 1989 and 2006: increasing incidence, but not in young adults. Oral Oncol. 2009, 45:e85-e89.
5. Conway D.I., Stockton D.L., Warnakulasuriya K.A., Ogden G., Macpherson L.M. Incidence of oral and oropharyngeal cancer in United Kingdom (1990-1999)-recent trends and regional variation. Oral Oncol. 2006, 42:586-592.
6. Robinson K.L., Macfarlane G.J. Oropharyngeal cancer incidence and mortality in Scotland: are rates still increasing?. Oral Oncol. 2003, 39:31-36.
7. Hammarstedt L., Dahlstrand H., Lindquist D., Onelov L., Ryott M., Luo J., Dalianis T., Ye W., Munck-Wikland E. The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol. 2007, 127:988-992.
8. Chaturvedi A.K., Engels E.A., Anderson W.F., Gillison M.L. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J. Clin. Oncol. 2008, 26:612-619.
9. Syrjänen S. HPV infections and tonsillar carcinoma. J. Clin. Pathol. 2004, 57:449-455.
10. Andl T., Kahn T., Pfuhl A., Nicola T., Erber R., Conradt C., Klein W., Helbig M., Dietz A., Weidauer H., Bosch F.X. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res. 1998, 58:5-13.
11. Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu L., Zahurak M.L., Daniel R.W., Viglione M., Symer D.E., Shah K.V., Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst. 2000, 92:709-720.
12. Psyrri A., Prezas L., Burtness B. Oropharyngeal cancer. Clin. Adv. Hematol. Oncol. 2008, 6:604-612.
13. D'Souza G., Kreimer A.R., Viscidi R., Pawlita M., Fakhry C., Koch W.M., Westra W.H., Gillison M.L. Case-control study of human papillomavirus and oropharyngeal cancer. New Engl. J. Med. 2007, 356:1944-1956.
14. Weinberger P.M., Yu Z., Haffty B.G., Kowalski D., Harigopal M., Brandsma J., Sasaki C., Joe J., Camp R.L., Rimm D.L., Psyrri A. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J. Clin. Oncol. 2006, 24:736-747.
15. Goon P.K., Stanley M.A., Ebmeyer J., Steinsträsser L., Upile T., Jerjes W., Bernal-Sprekelsen M., M Görner, Sudhoff H.H. HPV and head and neck cancer: a descriptive update. Head Neck Oncol. 2009, 1:36.
16. Wiest T., Schwarz E., Enders C., Flechtenmacher C., Bosch F.X. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002, 21:1510-1517.
17. Gillison M. Human papillomavirus and oropharyngeal cancer. Author reply. New Engl. J. Med. 2007, 357:1157-1158.
18. Duensing S., Münger K. Centrosome abnormalities and genomic instability induced by human papillomavirus oncoproteins. Prog. Cell Cycle Res. 2003, 5:383-391.
19. Crook T., Morgenstern J.P., Crawford L., Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J. 1989, 8:513-519.
20. Howley P.M. Role of the human papillomaviruses in human cancer. Cancer Res. 1991, 51(18 Suppl.):5019s-5022s.
21. Nasseri M., Gage J.R., Lorincz A., Wettstein F.O. Human papillomavirus type 16 immortalized cervical keratinocytes contain transcripts encoding E6, E7, and E2 initiated at the P97 promoter and express high levels of E7. Virology 1991, 184:131-140.
22. Hoffmann M., Ihloff A.S., Görögh T., Weise J.B., Fazel A., Krams M., Rittgen W., Schwarz E., Kahn T. p16INK4a overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int. J. Cancer 2010, 127:1595-1602.
23. Hansson B.G., Rosenquist K., Antonsson A., Wennerberg J., Schildt E.B., Bladström A., Andersson G. Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. Acta Otolaryngol. 2005, 125:1337-1344.
24. Gillison M. Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr. Opin. Oncol. 2009, 21:439-444.
25. Licitra L., Perrone F., Bossi P., Suardi S., Mariani L., Artusi R., Oggionni M., Rossini C., Cantù G., Squadrelli M., Quattrone P., Locati L.D., Bergamini C., Olmi P., Pierotti M.A., Pilotti S. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J. Clin. Oncol. 2006, 24:5630-5636.
26. Mellin H., Dahlgren L., Munck-Wikland E., Lindholm J., Rabbani H., Kalantari M., Dalianis T. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int. J. Cancer 2002, 102:152-158.
27. Dahlstrand H.M., Dalianis T. Presence and influence of human papillomaviruses (HPV) in tonsillar cancer. Adv. Cancer Res. 2005, 93:59-89.
28. D'Souza G., Agrawal Y., Halpern J., Bodison S., Gillison M.L. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J. Infect. Dis. 2009, 199:1263-1269.
29. Vaccarella S., Franceschi S., Herrero R., Muñoz N., Snijders P.J., Clifford G.M., Smith J.S., Lazcano-Ponce E., Sukvirach S., Shin H.R., de Sanjosé S., Molano M., Matos E., Ferreccio C., Anh P.T., Thomas J.O., Meijer C.J. IARC HPV Prevalence Surveys Study Group, Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol. Biomark. Prev. 2006, 15:326-333.
30. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol. Biomark. Prev. 2005, 14:467-475.
31. Termine N., Panzarella V., Falaschini S., Russo A., Matranga D., Lo Muzio L., Campisi G. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann. Oncol. 2008, 19:1681-1690.
32. Smeets S.J., Hesselink A.T., Speel E.J., Haesevoets A., Snijders P.J., Pawlita M., Meijer C.J., Braakhuis B.J., Leemans C.R., Brakenhoff R.H. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int. J. Cancer 2007, 121:2465-2472.
33. Licitra L., Felip E. Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow up. Ann. Oncol. 2009, 20(Suppl. 4):iv121-iv122.
34. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology, 2010, <> (accessed 20.12.10). http://www.nccn.org/p.
35. Haigentz M., Silver C.E., Corry J., Genden E.M., Takes R.P., Rinaldo A., Ferlito A. Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. Eur. Arch. Otorhinolaryngol. 2009, 266:1845-1855.
36. Hicks W.L., Kuriakose M.A., Loree T.R., Maamoun S., Mullins A., Orner J.B., Bakamjian V.Y., Shedd D.P. Surgery versus radiation therapy as single-modality treatment of tonsillar fossa carcinoma: The Roswell Park Cancer Institute experience (1971-1991). Laryngoscope 1998, 108:1014-1019.
37. Calais G., Alfonsi M., Bardet E., Sire C., Germain T., Bergerot P., Rhein B., Tortochaux J., Oudinot P., Bertrand P. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J. Natl. Cancer Inst. 1999, 91:2081-2086.
38. Denis F., Garaud P., Bardet E., Alfonsi M., Sire C., Germain T., Bergerot P., Rhein B., Tortochaux J., Calais G. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J. Clin. Oncol. 2004, 22:69-76.
39. Hoffmann M., Görögh T., Gottschlich S., Lohrey C., Rittgen W., Ambrosch P., Schwarz E., Kahn T. Human papillomaviruses in head and neck cancer: 8-year survival analysis of 73 patients. Cancer Lett. 2005, 218:199-206.
40. Reimers N., Kasper H.U., Weissenborn S.J., Stützer H., Preuss S.F., Hoffmann T.K., Speel E.J., Dienes H.P., Pfister H.J., Guntinas-Lichius O., Klussmann J.P. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int. J. Cancer 2007, 120:1731-1738.
41. Ihloff A.S., Petersen C., Hoffmann M., Knecht R., Tribius S. Human papilloma virus in locally advanced stage III/IV squamous cell cancer of the oropharynx and impact on choice of therapy. Oral Oncol. 2010, 46:705-711.
42. O'Sullivan B., Huang S., Perez-Ordonez B., Liu F., Massey C., Weinreb I., Chen E., Cummings B., Kim J., Waldron J. Outcome of radiotherapy alone in HPV associated oropharyngeal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010, 78. (Abstract 132).
43. Koutcher L.D., Sherman E., Carlson D., Katabi N., Fury M., Wolden S., Zhang Z., Mo Q., Pfister D., Lee N. Cisplatin (CDDP) and radiation (RT) versus cetuximab (C) and RT in the context of human papillomavirus (HPV) and p16 in the treatment of locally advanced head and neck cancer (LAHNC). Int. J. Radiat. Oncol. Biol. Phys. 2010, 78. (Abstract 133).
44. Gay H.A., Spencer C.R., Lewis J.S., Liu E., El Naqa I., Adkins D., Deasy J.O., Nussenbaum B., Haughey B.H., Thorstad W.L. Outcomes of p16 positive oropharyngeal squamous cell carcinoma treated with postoperative adjuvant IMRT chemotherapy: a retrospective analysis. Int. J. Radiat. Oncol. Biol. Phys. 2010, 78. (Abstract 134).
45. Worden F.P., Kumar B., Lee J.S., Wolf G.T., Cordell K.G., Taylor J.M., Urba S.G., Eisbruch A., Teknos T.N., Chepeha D.B., Prince M.E., Tsien C.I., D'Silva N.J., Yang K., Kurnit D.M., Mason H.L., Miller T.H., Wallace N.E., Bradford C.R., Carey T.E. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J. Clin. Oncol. 2008, 26:3138-3146.
46. Kumar B., Cordell K.G., Lee J.S., Worden F.P., Prince M.E., Tran H.H., Wolf G.T., Urba S.G., Chepeha D.B., Teknos T.N., Eisbruch A., Tsien C.I., Taylor J.M., D'Silva N.J., Yang K., Kurnit D.M., Bauer J.A., Bradford C.R., Carey T.E. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J. Clin. Oncol. 2008, 26:3128-3137.
47. Fakhry C., Westra W.H., Li S., Cmelak A., Ridge J.A., Pinto H., Forastiere A., Gillison M.L. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst. 2008, 100:261-269.
48. Jo S., Juhasz A., Zhang K., Ruel C., Loera S., Wilczynski S.P., Yen Y., Liu X., Ellenhorn J., Lim D., Paz B., Somlo G., Vora N., Shibata S. Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. Anticancer Res. 2009, 29:1467-1474.
49. Kies M.S., Holsinger F.C., Lee J.J., William W.N., Glisson B.S., Lin H.Y., Lewin J.S., Ginsberg L.E., Gillaspy K.A., Massarelli E., Byers L., Lippman S.M., Hong W.K., El-Naggar A.K., Garden A.S., Papadimitrakopoulou V. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J. Clin. Oncol. 2010, 28:8-14.
50. Settle K., Posner M.R., Schumaker L.M., Tan M., Suntharalingam M., Goloubeva O., Strome S.E., Haddad R.I., Patel S.S., Cambell E.V., Sarlis N., Lorch J., Cullen K.J. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev. Res. (Phila. Pa.) 2009, 2:776-781.
51. Posner M.R., Lorch J.H., Goloubeva O., Tan M., Schumaker L., Sarlis N.J., Haddad R.I., Cullen K.J. Oropharynx cancer (OPC) in TAX 324: human papillomavirus (HPV) and survival. J. Clin. Oncol. 2010, 28(15s). (Suppl., abstr. 5525).
52. Rischin D., Young R.J., Fisher R., Fox S.B., Le Q.T., Peters L.J., Solomon B., Choi J., O'Sullivan B., Kenny L.M., McArthur G.A. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J. Clin. Oncol. 2010, 28:4142-4148.
53. Ang A.K., Harris J., Wheeler R., Weber R., Rosenthal D.I., Nguyen-Tân P.F., Westra W.H., Chung C.H., Jordan R.C., Lu C., Kim H., Axelrod R., Silverman C.C., Redmond K.P., Gillison M.L. Human papillomavirus and survival of patients with oropharyngeal cancer. New Engl. J. Med. 2010, 363:24-35.
54. Lassen P., Eriksen J.G., Hamilton-Dutoit S., Tramm T., Alsner J., Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2009, 27:1992-1998.
55. Lassen P., Eriksen J.G., Hamilton-Dutoit S., Tramm T., Alsner J., Overgaard J. Danish Head and Neck Cancer Group (DAHANCA), HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother. Oncol. 2010, 94:30-35.
56. J. Palefsky, for the Male Quadrivalent HPV Vaccine Efficacy Trial Team, Efficacy of Gardasil® in men aged 16-26 years naïve to vaccine HPV types at baseline: the latest data, in: Presented at European Research Organization on Genital Infection and Neoplasia 2010, Monte Carlo, Monaco, February 17-20, 2010 (abstr. TC-4-2).
57. Brisson M., Van de Velde N., Boily M.C. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009, 12:343-351.
58. Elbasha E.H., Dasbach E.J., Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis. 2007, 13:28-41.
59. Taira A.V., Neukermans C.P., Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg. Infect. Dis. 2004, 10:1915-1923.
60. C. Wong, Z. Berkowitz, J.W. Lee, M. Saraiya, National HPV Vaccine Uptake and vaccination predictors and barriers for girls 8-17 years old-United States, 2008 National STD Prevention Conference, Atlanta, GA, USA, 2010 (abstr. LBb).
61. Maxwell J.H., Kumar B., Feng F.Y., Worden F.P., Lee J.S., Eisbruch A., Wolf G.T., Prince M.E., Moyer J.S., Teknos T.N., Chepeha D.B., McHugh J.B., Urba S.G., Stoerker J., Walline H.M., Kurnit D.M., Cordell K.G., Davis S.J., Ward P.D., Bradford C.R., Carey T.E. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin. Cancer Res. 2010, 16:1226-1235.
62. Peters L.J., O'Sullivan B., Giralt J., Fitzgerald T.J., Trotti A., Bernier J., Bourhis J., Yuen K., Fisher R., Rischin D. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J. Clin. Oncol. 2010, 28:2996-3001.